Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
M. Kulesza
Observed name:
Michal Kulesza
Observed institution:
Medical University of Białystok
OpenAlex ID:
A5015457343
An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
2025
·
Herve Ghesquieres
, Malgorzata Krawczyk-Kulis
, et al.
·
Blood
·
1
PDF
T045 Evaluation of chemokine CXCL1, CXCL12 and metalloproteinase MMP-9 as diagnostic markers of breast cancer
2022
·
J. Motyka
, M. Kulesza
, et al.
·
Clinica Chimica Acta
·
1
The plasma levels and diagnostic utility of Galactine 3 (GAL-3) in ovarian cancer patients
2024
·
P. Lawicki
, M. Lawicki
, et al.
·
Clinica Chimica Acta
The utility of galectin 9 (GAL-9) in diagnostic of ovarian cancer patients
2024
·
S. Lawicki
, A. Kicmann
, et al.
·
Clinica Chimica Acta
T047 Evaluation of cytokines M-CSF, VEGF and metalloproteinase MMP-9 as diagnostic markers of ovarian cancer
2022
·
P. Ławicki
, E.G. Będkowska
, et al.
·
Clinica Chimica Acta
Show more works
View as search
Works count:
5
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type
